Evidence map›Paper›PMID 32146726›Full record

ArticleMolecular oncology2020

PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.

Neha Singh, Sathish K R Padi, Jeremiah J Bearss, Ritu Pandey, Koichi Okumura, Himisha Beltran, Jin H Song, Andrew S Kraft, Virginie Olive

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Mouse Trophoblast Stem Cells Are Deficient in TNFα-Activated NFκB Signaling Pathway and Inflammatory Response.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Neha SinghUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Sathish K R PadiUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Jeremiah J BearssUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Ritu PandeyUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Koichi OkumuraUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jin H SongUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.ORCID 0000-0002-0123-2909
Andrew S KraftUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.ORCID 0000-0003-3417-4845
Virginie OliveUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
University of Arizona · USDana-Farber Cancer Institute · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT InhibitorsR01CA173200 · NCI · UNIVERSITY OF ARIZONA · PI KRAFT, ANDREW S · 2013 to 2017
$1.6M
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA173200
6 · The paper itself

Abstract

The proviral integration site for Moloney murine leukemia virus (PIM) serine/threonine kinases have an oncogenic and prosurvival role in hematological and solid cancers. However, the mechanism by which these kinases drive tumor growth has not been completely elucidated. To determine the genes controlled by these protein kinases, we carried out a microarray analysis in T-cell acute lymphoblastic leukemia (T-ALL) comparing early progenitor (ETP-ALL) cell lines whose growth is driven by PIM kinases to more mature T-ALL cells that have low PIM levels. This analysis demonstrated that the long noncoding RNA (lncRNA) H19 was associated with increased PIM levels in ETP-ALL. Overexpression or knockdown of PIM in these T-ALL cell lines controlled the level of H19 and regulated the methylation of the H19 promoter, suggesting a mechanism by which PIM controls H19 transcription. In these T-ALL cells, the expression of PIM1 induced stem cell gene expression (SOX2, OCT-4, and NANOG) through H19. Identical results were found in prostate cancer (PCa) cell lines where PIM kinases drive cancer growth, and both H19 and stem cell gene levels. Small molecule pan-PIM inhibitors (PIM-i) currently in clinical trials reduced H19 expression in both of these tumor types. Importantly, the knockdown of H19 blocked the ability of PIM to induce stem cell genes in T-ALL cells, suggesting a novel signal transduction cascade. In PCa, increases in SOX2 levels have been shown to cause both resistance to the androgen deprivation therapy (ADT) and the induction of neuroendocrine PCa, a highly metastatic form of this disease. Treatment of PCa cells with a small molecule pan-PIM-i reduced stem cell gene transcription and enhanced ADT, while overexpression of H19 suppressed the ability of pan-PIM-i to regulate hormone blockade. Together, these results demonstrate that the PIM kinases control the level of lncRNA H19, which in turn modifies stem cell gene transcription regulating tumor growth.

Indexed as

Androgen AntagonistsCell Line, TumorCell SurvivalGene Knockdown TechniquesHumansMaleNanog Homeobox ProteinOctamer Transcription Factor-3Oligonucleotide Array Sequence AnalysisOrganoidsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPromoter Regions, GeneticProstatic NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1RNA, Long NoncodingAndrogen AntagonistsH19 long non-coding RNANanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1proto-oncogene proteins pimRNA, Long NoncodingSOX2 protein, humanSOXB1 Transcription Factorsandrogen deprivation therapy resistanceH19Pim kinaseprostate cancerSOX2T-ALL

Identifiers

PMID32146726
PMCPMC7191193
OpenAlexW3010757601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.